Tech firm Bioliberty has secured £2.2million in funding to develop its unique robotic glove to help restore upper limb mobility after stroke.
Bioliberty has created the Lifeglov – a soft robotic glove which supports rehabilitation for both the closing and opening strength of the hand.
The glove – unique in the market – monitors key metrics related to upper limb mobility and can demonstrate improvement as the patient progresses through their rehab.
The Lifeglov is accompanied by a Digital Therapy Platform, which provides the patient with tailored exercises to help develop natural hand strength.
The technology, which is targeting launch in the US in 2024, adds further to the options around remote rehab for stroke survivors, and can support therapists in widening options around digital rehab tools.
To support its further development, Edinburgh-based Bioliberty has raised £2.2million through a funding round led by The funding round was led by Archangels, the world’s longest running business angel investment syndicate, with participation from Eos Advisory, Old College Capital and Hanna Capital SEZC.
The new funding will allow Bioliberty to complete development of the trial product and finalise the development of its platform.
The funding is also anticipated to fund the business through obtaining FDA approval and early commercial engagement in the US with rehabilitation clinics.
The initial application for Lifeglov is in the upper limb rehabilitation market, but it is anticipated that the technology will have a broad range of clinical applications including lower limb.
The business was co-founded in 2020 by Rowan Armstrong, Conan Bradley, Ross O’Hanlon and Shea Quinn .
Rowan Armstrong, CEO at Bioliberty, said: “Our aim at Bioliberty is to empower every human to live a longer independent life by providing assistive robotics and rehabilitative technologies.
“The Lifeglov is a first step on this journey and the funding announced today will allow us to complete its development, along with our software platform, while preparing the runway for our US sales push.
“We’re confident in our technology and excited by the benefits it can deliver for both patients and occupational therapists.”
Niki McKenzie, joint managing director at Archangels, said: “Bioliberty has developed a highly effective solution for helping patients with hand weakness, with the potential to improve the quality of life for millions worldwide.
“We believe its technology has far-reaching benefits beyond this first application, providing the business with an excellent opportunity to grow quickly from its base here in Scotland.
“Archangels is excited to be supporting the team as they finalise what we hope will be the first of many products and start scaling up their sales activity.”
- Opinion3 weeks ago
Is 2024 the year football finally takes the lead on addressing brain threat?
- Community neuro rehab2 weeks ago
Neurological speech and language therapy
- Premium content3 weeks ago
Interview: Advances and challenges in Motor Neurone Disease research
- News5 days ago
Daily Round Up: Tuesday 20 February
- Neuropsychology news4 weeks ago
Brain pathway could shed new light on neurodegenerative diseases
- News2 weeks ago
Chroma launches UK’s first Creative Arts Therapies Expert Witness Service
- News3 weeks ago
Interview: How spasticity treatment gaps are holding back rehab outcomes
- Community neuro rehab2 weeks ago
Bushcraft and ABI rehab at Calvert Reconnections